Janna Bashar

Dr. Janna Bashar

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2024 in Antibodies
Verified
Journal Article
Open access
PDF file
JBJanna Bashar
Janna Bashar
ZZZihao Zheng
Zihao Zheng
AMAisha M. Mergaert
Aisha M. Mergaert
RARyan R. Adyniec
Ryan R. Adyniec
Srishti GuptaSrishti Gupta
Srishti Gupta
MSMiriam Shelef
Miriam Shelef
Background: Autoantibodies are commonly used as biomarkers in autoimmune diseases, but there are limitations. For example, autoantibody biomarkers have poor sensitivity or specificity in systemic lupus erythematosus and do not exist in the spondyloarthropathies, impairing diagnosis and treatment. While autoantibodies suitable for strong biomarkers may not exist in these conditions, another possibility is that technology has limited their discovery. The purpose of this study was to use a novel high-density peptide array that enables the evaluation of IgG binding to every possible linear antigen in the entire human peptidome, as well as a novel machine learning approach that incorporates ELISA validation predictability in order to discover autoantibodies that could be developed into sensitive and specific markers of lupus or spondyloarthropathy. Methods: We used a peptide array containing the human peptidome, several viral peptidomes, and key post-translational modifications (6 million peptides) to quantify IgG binding in lupus, spondyloarthropathy, rheumatoid arthritis, Sjögren’s disease, and control sera. Using ELISA data for 70 peptides, we performed a random forest analysis that evaluated multiple array features to predict which peptides might be good biomarkers, as confirmed by ELISA. We validated the peptide prediction methodology in rheumatoid arthritis and COVID-19, conditions for which the antibody repertoire is well-understood, and then evaluated IgG binding by ELISA to peptides that we predicted would be highly bound specifically in lupus or spondyloarthropathy. Results: Our methodology performed well in validation studies, but peptides predicted to be highly and specifically bound in lupus or spondyloarthropathy could not be confirmed by ELISA. Conclusions: In a comprehensive evaluation of the entire human peptidome, highly sensitive and specific IgG autoantibodies were not identified in lupus or spondyloarthropathy. Thus, the pathogenesis of lupus and spondyloarthropathy may not depend upon unique autoantigens, and other types of molecules should be sought as optimal biomarkers in these conditions.

5 October 2023
Verified
Conference Paper
Closed access
PDF file
ABAidana Beisenova
Aidana Beisenova
WAWihan Adi
Wihan Adi
JBJanna Bashar
Janna Bashar
MVMonniiesh Velmurugan
Monniiesh Velmurugan
KGKenzie B. Germanson
Kenzie B. Germanson
Filiz YesilkoyFiliz Yesilkoy
Filiz Yesilkoy
Surveillance of population immunity against infectious diseases is critical for pandemic management and risk assessment of future outbreaks. However, current serological tests fall short in accurately identifying immunity profiles from diverse populations. We present a label-free, rapid, multiplexed, and variant-sensitive nanoplasmonic biosensor to quantify antibodies against multiple SARS-CoV-2 antigens from small human blood samples. We combined a machine learning model with antigen-specific antibody patterns measured from four different cohorts with known COVID-19 immunity. Subsequently, we tested our model on 100 blind human samples and determine that our findings are consistent with public epidemiological data showing that our nanobiosensor can help monitor population health during a pandemic.